NCT05818514View on ClinicalTrials.gov

A PET Study to Determine Biodistribution and Binding Characteristics of [11C]AZ14132516 in Healthy Participants

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

April 27, 2023

Primary Completion Date

July 11, 2023

Study Completion Date

July 11, 2023

Conditions
Healthy Volunteers
Interventions
DRUG

[11C]AZ14132516

Injection of radioligand for PET examinations

Trial Locations (1)

171 64

Research Site, Solna

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY